Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL28970472 | 0.96 | FFAR3 (0.58) | — | |
| Acetic Acid SCHEMBL9659096 | 0.91 | FFAR3 (0.64) | — | |
| Acetic Acid SCHEMBL174567 | 0.91 | — | — | |
| Acetic Acid SCHEMBL28843588 | 0.91 | FFAR3 (0.64) | — | |
| Acetic Acid SCHEMBL574619 | 0.91 | FFAR3 (0.64) | — | |
| Acetic Acid SCHEMBL16563111 | 0.87 | — | — | |
| Acetic Acid SCHEMBL3042211 | 0.87 | — | — | |
| Acetic Acid SCHEMBL1679496 | 0.87 | — | — | |
| Acetic Acid SCHEMBL24229 | 0.87 | FFAR3 (0.58) | — | |
| Acetic Acid SCHEMBL5877355 | 0.87 | FFAR3 (0.58) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4643858-A1 | METHODS AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF UTERINE DISEASE | Institut National de la Santé et de la Recherche Médicale (FR) | 2025-11-05 | — | — | EP | claimed |
| WO-2024175760-A1 | METHODS FOR THE TREATMENT OF ENDOMETRIOSIS | Institut National de la Santé et de la Recherche Médicale (FR) | 2024-08-29 | — | — | WO | claimed |
| US-20230000832-A1 | USE OF NEUROPILIN ANTAGONISTS FOR THE TREATMENT OF ENDOMETRIOSIS | ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP) (FR) | 2023-01-05 | — | — | US | claimed |
| EP-4065224-A1 | USE OF NEUROPILIN ANTAGONISTS FOR THE TREATMENT OF ENDOMETRIOSIS | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2022-10-05 | — | — | EP | claimed |
| WO-2021105368-A1 | USE OF NEUROPILIN ANTAGONISTS FOR THE TREATMENT OF ENDOMETRIOSIS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2021-06-03 | — | — | WO | claimed |
| US-20170049785-A1 | ESTROGEN COMBINATION FOR TREATMENT OF MULTIPLE SCLEROSIS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-02-23 | — | — | US | claimed |
| EP-4643858-A1 | METHODS AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF UTERINE DISEASE | Institut National de la Santé et de la Recherche Médicale (FR) | 2025-11-05 | — | — | EP | disclosed |
| WO-2024175760-A1 | METHODS FOR THE TREATMENT OF ENDOMETRIOSIS | Institut National de la Santé et de la Recherche Médicale (FR) | 2024-08-29 | — | — | WO | disclosed |
| US-20230000832-A1 | USE OF NEUROPILIN ANTAGONISTS FOR THE TREATMENT OF ENDOMETRIOSIS | ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP) (FR) | 2023-01-05 | — | — | US | disclosed |
| EP-4065224-A1 | USE OF NEUROPILIN ANTAGONISTS FOR THE TREATMENT OF ENDOMETRIOSIS | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2022-10-05 | — | — | EP | disclosed |
| WO-2021105368-A1 | USE OF NEUROPILIN ANTAGONISTS FOR THE TREATMENT OF ENDOMETRIOSIS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2021-06-03 | — | — | WO | disclosed |
| US-10799512-B2 | Estrogen combination for treatment of multiple sclerosis | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-10-13 | — | — | US | disclosed |
| US-20170049785-A1 | ESTROGEN COMBINATION FOR TREATMENT OF MULTIPLE SCLEROSIS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-02-23 | — | — | US | disclosed |
| CN-102718775-B | As the Macrocyclic quinazoline derivatives of antiproliferative | JANSSEN PHARMACEUTICA N.V. (BE) | 2016-02-17 | — | — | CN | disclosed |